Evaluation of TNF-α, Apelin and Visfatin in a sample of Iraqi patients with newly diagnosed Type2 Diabetes Mellitus

Abstract

Type 2 diabetes mellitus, previously referred to as "Noninsulin-dependent diabetes" or "adult-onset diabetes," accounts for 90-95 % of all diabetes. This type involves people who suffer from relative (rather than absolute) insulin deficiency and suffer from peripheral insulin resistances. The present study aimed to detect serum marker in newly diagnosed type two diabetic mellitus patients in Baghdad province through evaluation of Tumor necrosis factor alpha, Apelin and Visfatin levels. In the current study, (140) participants were recruited and grouped into: patients group (70 patients with newly diagnosed T2DM, and (70 individuals as apparently healthy control group). In the current study, age and sex matched healthy individuals were enrolled. Results showed the serum level of TNF-α, Apelin and Visfatin were estimated by the use of ELISA technique. Furthermore, the mean serum level of TNF-α, Apelin and Visfatin in T2DM patients was 366.08± 76.99 pg/ml, 96.61± 46.62 pg/ml and 9.59± 3.62ng/ml, respectively, which was higher than that of healthy subjects (175.86± 9.92pg/ml , 15.67± 1.74 pg/ml and 2.15± 0.33ng/ml, respectively) with highly significant differences (P<0.0001). Therefore, TNF-α, Visfatin and Apelin can be applies as a diagnostic biomarker and as useful tools for predict ion and prevention of pre DM complications.